BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 17174649)

  • 1. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.
    Rienstra M; Smit MD; Nieuwland W; Tan ES; Wiesfeld AC; Anthonio RL; Van den Berg MP; Van Veldhuisen DJ; Van Gelder IC
    Am Heart J; 2007 Jan; 153(1):120-6. PubMed ID: 17174649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation predicts appropriate shocks in primary prevention implantable cardioverter-defibrillator patients.
    Smit MD; Van Dessel PF; Rienstra M; Nieuwland W; Wiesfeld AC; Tan ES; Anthonio RL; Van Veldhuisen DJ; Van Gelder IC
    Europace; 2006 Aug; 8(8):566-72. PubMed ID: 16864611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
    Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
    Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure.
    Singh SN; Poole J; Anderson J; Hellkamp AS; Karasik P; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2006 Nov; 152(5):974.e7-11. PubMed ID: 17070171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation of advanced heart failure symptoms to risk of inappropriate defibrillator shocks.
    Hreybe H; Ezzeddine R; Barrington W; Bazaz R; Jain S; Ngwu O; Saba S
    Am J Cardiol; 2006 Feb; 97(4):544-6. PubMed ID: 16461053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of appropriate defibrillator therapy among patients with an implantable defibrillator that delivers cardiac resynchronization therapy.
    Desai AD; Burke MC; Hong TE; Kim S; Salem Y; Yong PG; Knight BP
    J Cardiovasc Electrophysiol; 2006 May; 17(5):486-90. PubMed ID: 16684019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of atrial fibrillation in implantable cardioverter-defibrillator patients.
    Borleffs CJ; van Rees JB; van Welsenes GH; van der Velde ET; van Erven L; Bax JJ; Schalij MJ
    J Am Coll Cardiol; 2010 Mar; 55(9):879-85. PubMed ID: 20185038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator shocks in patients with a left ventricular assist device.
    Ambardekar AV; Allen LA; Lindenfeld J; Lowery CM; Cannon AP; Cleveland JC; Brieke A; Sauer WH
    J Heart Lung Transplant; 2010 Jul; 29(7):771-6. PubMed ID: 20347337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.
    Obeyesekere MN; Chan W; Stub D; Prabhu S; Teo EP; Toogood G; Mariani J; Broughton A; Kistler PM
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):696-704. PubMed ID: 20059719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators.
    Goldenberg I; Moss AJ; McNitt S; Zareba W; Daubert JP; Hall WJ; Andrews ML;
    J Cardiovasc Electrophysiol; 2006 Sep; 17(9):931-6. PubMed ID: 16759297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction.
    Chan PS; Chow T; Kereiakes D; Schloss EJ; Waller T; Eagle K; Hayward RA; Vijan S
    Arch Intern Med; 2006 Nov; 166(20):2228-33. PubMed ID: 17101941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).
    Singh JP; Hall WJ; McNitt S; Wang H; Daubert JP; Zareba W; Ruskin JN; Moss AJ;
    J Am Coll Cardiol; 2005 Nov; 46(9):1712-20. PubMed ID: 16256874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of ventricular tachyarrhythmia by treatment of atrial fibrillation in ICD patients with dual-chamber implantable cardioverter/defibrillators capable of atrial therapy delivery: the REVERT-AF Study.
    Gradaus R; Seidl K; Korte T; Himmrich E; Wieneke H; Schuchert A; Bauer W; Gerss J; Wollmann CG; Borggrefe M; Böcker D
    Europace; 2007 Jul; 9(7):534-9. PubMed ID: 17440005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinus rhythm restoration by catheter ablation in patients with long-lasting atrial fibrillation and congestive heart failure: impact of the left ventricular ejection fraction improvement on the implantable cardioverter defibrillator insertion indication.
    Bortone A; Boveda S; Pasquié JL; Pujadas-Berthault P; Marijon E; Appetiti A; Albenque JP
    Europace; 2009 Aug; 11(8):1018-23. PubMed ID: 19556251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy.
    Desai H; Aronow WS; Ahn C; Tsai FS; Lai HM; Gandhi K; Amin H; Frishman WH; Kalapatapu K; Cohen M; Sorbera C
    J Cardiovasc Pharmacol Ther; 2010 Mar; 15(1):37-40. PubMed ID: 19966176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
    Moss AJ; Greenberg H; Case RB; Zareba W; Hall WJ; Brown MW; Daubert JP; McNitt S; Andrews ML; Elkin AD;
    Circulation; 2004 Dec; 110(25):3760-5. PubMed ID: 15583079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks.
    van Boven N; Theuns D; Bogaard K; Ruiter J; Kimman G; Berman L; VAN DER Ploeg T; Kardys I; Umans V
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1116-22. PubMed ID: 23889733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.